Mark C Connelly
Overview
Explore the profile of Mark C Connelly including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
1605
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Foulk B, Schaffer M, Gross S, Rao C, Smirnov D, Connelly M, et al.
Br J Haematol
. 2017 Nov;
180(1):71-81.
PMID: 29105742
We have developed an automated assay to enumerate and characterize circulating multiple myeloma cells (CMMC) from peripheral blood of patients with plasma cell disorders. CMMC show expression of genes characteristic...
2.
Muse E, Kramer E, Wang H, Barrett P, Parviz F, Novotny M, et al.
Sci Rep
. 2017 Sep;
7(1):12268.
PMID: 28947747
Chest pain is a leading reason patients seek medical evaluation. While assays to detect myocyte death are used to diagnose a heart attack (acute myocardial infarction, AMI), there is no...
3.
Salgia R, Weaver R, McCleod M, Stille J, Yan S, Roberson S, et al.
Invest New Drugs
. 2017 Mar;
35(3):334-344.
PMID: 28299514
Background Circulating tumor cells (CTCs) and chemokine (C-X-C motif) receptor 4 (CXCR4) expression in CTCs and tumor tissue were evaluated as prognostic or predictive markers of CXCR4 peptide antagonist LY2510924...
4.
Paoletti C, Larios J, Muniz M, Aung K, Cannell E, Darga E, et al.
Mol Oncol
. 2016 May;
10(7):1078-85.
PMID: 27178224
Fulvestrant is a dose dependent selective estrogen receptor (ER) down-regulator (SERD) used in ER-positive metastatic breast cancer (MBC). Nearly all patients develop resistance. We performed molecular analysis of circulating tumor...
5.
Paoletti C, Muniz M, Thomas D, Griffith K, Kidwell K, Tokudome N, et al.
Clin Cancer Res
. 2014 Nov;
21(11):2487-98.
PMID: 25381338
Background: Endocrine therapy (ET) fails to induce a response in one half of patients with hormone receptor (HR)-positive metastatic breast cancer (MBC), and almost all will eventually become refractory to...
6.
Smerage J, Budd G, Doyle G, Brown M, Paoletti C, Muniz M, et al.
Mol Oncol
. 2013 Mar;
7(3):680-92.
PMID: 23538216
Background: Enumeration of circulating tumor cells (CTC) from whole blood permits monitoring of patients with breast carcinoma. Analysis of apoptosis & Bcl-2 expression in CTC might add additional prognostic and...
7.
Zweitzig D, Smirnov D, Connelly M, Terstappen L, OHara S, Moran E
Mol Cell Biochem
. 2007 Aug;
306(1-2):255-60.
PMID: 17694278
As an approach to understanding the factors that activate expression of tumor progression genes, the role of physiological stress in the activation of a panel of tumor cell markers was...
8.
Rowand J, Martin G, Doyle G, Miller M, Pierce M, Connelly M, et al.
Cytometry A
. 2007 Jan;
71(2):105-13.
PMID: 17226859
Background: A lack of standardized assays and consensus of cell definition has lead to a wide variation in the reported range of circulating endothelial cells (CECs). Methods: An automated rare...
9.
Smirnov D, Foulk B, Doyle G, Connelly M, Terstappen L, OHara S
Cancer Res
. 2006 Mar;
66(6):2918-22.
PMID: 16540638
Increased numbers of endothelial cells are observed in peripheral blood of cancer patients. These circulating endothelial cells (CECs) may contribute to the formation of blood vessels in the tumor or...
10.
Smirnov D, Zweitzig D, Foulk B, Miller M, Doyle G, Pienta K, et al.
Cancer Res
. 2005 Jun;
65(12):4993-7.
PMID: 15958538
Metastases from primary tumors are responsible for most cancer deaths. It has been shown that circulating tumor cells (CTCs) can be detected in the peripheral blood of patients with a...